Edition:
United States

CytRx Corp (CYTR.PH)

CYTR.PH on Philadelphia Stock Exchange

0.40USD
12 Oct 2017
Change (% chg)

$-0.01 (-1.61%)
Prev Close
$0.41
Open
$0.41
Day's High
$0.41
Day's Low
$0.40
Volume
1,326
Avg. Vol
3,210
52-wk High
$0.98
52-wk Low
$0.37

Select another date:

Mon, Oct 2 2017

BRIEF-CytRx Corp provides business update and highlights future plans

* CytRx Corp provides business update and highlights future plans

BRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​

* CytRx Corp - proxy advisory firm Glass Lewis & Co. Recommends CytRx Corp stockholders vote "for" proposed reverse stock split​ Source text for Eikon: Further company coverage:

BRIEF-CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

* CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

BRIEF-Cytrx reports Q2 loss per share $0.10

* Cytrx corp - ‍cash, cash equivalents and short-term investments of $55.0 million as of june 30, 2017​ Source text for Eikon: Further company coverage:

BRIEF-Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin

* CytRX Corporation announces global strategic license with Nantcell Inc for Aldoxorubicin, an albumin mediated chemotherapeutic

BRIEF-Cytrx announces update on regulatory pathway for aldoxorubicin in soft tissue sarcomas

* Cytrx announces update on the regulatory pathway for aldoxorubicin in soft tissue sarcomas

BRIEF-Cytrx reports Q1 loss per share $0.10

* Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin

BRIEF-Cytrx Corp prices $15 mln public offering of common stock

* Cytrx Corporation announces pricing of $15 million public offering of common stock

Select another date: